PSTV earnings analysis
What we found in PSTV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Plus Therapeutics reported Q1 2026 results showing revenue of $1.0 million, a decrease from $1.1 million in Q1 2025. However, the diluted EPS improved significantly to -$1.05 from -$29.86 in the same quarter last year. The company completed a public offering generating $15 million, increasing cash balances to a total of $3.0 million by the end of the quarter.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Stable Revenue Figures
- Reported revenue for Q1 2026 was $1.0 million, unchanged from Q4 2025 but down from $1.1 million in Q1 2025.
- Significant EPS Improvement
- Diluted EPS for Q1 2026 improved to -$1.05, significantly better than -$29.86 in Q1 2025.
- Cash Surplus Boost
- Completed a public offering that raised $15 million, bringing cash equivalents to $3.0 million.
- Increased R&D Spending
- Research and development expenses surged to $2.86 million from $1.75 million in the same period last year.
- Operating Loss Reduced
- The operating loss was $6.9 million for Q1 2026, less than the prior year loss of $14.1 million.
- Significant Equipment Investments
- Invested $8.5 million in capital expenditures during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Operational Costs
- R&D costs spiked by approximately $1.1 million compared to the same period last year, reflecting ongoing development challenges.
- Cash Flow Concerns
- Net cash used in operating activities reached $6.2 million, a concerning trend as the company continues to burn cash.
- Dependence on External Funding
- Dependence on future financings increases risk, as the company acknowledges ongoing needs to raise capital.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.05
What they said about what is next.
No specific financial guidance disclosed; management indicates growth in diagnostic revenue expected in 2026.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PSTV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever